Roche gains accelerated approval from the FDA for latest cancer therapy
Considering a recent Phase II trial, the FDA have granted accelerated approval to Roche and Genentech for their bispecfic therapeutic for the treatment of types of lymphoma.
In amongst a flurry of approvals for cancer therapeutics in the last few months, Roche, working with Genentech, adds their treatment, Columvi, to the list.
Columvi, otherwise known as glofitamab, is a bispecific therapy used to treat large B-cell lymphoma, more specifically it is suitable for use in adults with diffuse large B-cell lymphoma (DLBCL) or large B-cell lymphoma (LBCL) that either has relapsed, hasn’t responded to other lines of therapy, or in patients who have had 2 or more treatment options already.
The approval falls under the FDA’s accelerated approval programme, and was granted very quickly, even with a shorter priority review timeline. This brings the treatment up level with Epkinly from AbbVie and Genmab, the other CD20xCD3 bispecific T-cell engager on the market.
The approval comes after showing good consistent results in a Phase II clinical trial, however, unlike Epkinly, the drug from Roche doesn’t address potential treatment of high-grade B-cell lymphoma, even though patients with this presentation made up 7% of the trial subjects. Even so, DLBCL represented the larger cohort and was a main focus of the study.
The treatment is administered currently as an intravenous infusion, which is less accessible than Epkinly, which can be given as a subcutaneous injection, but Roche are working on a formulation that could be administered subcutaneously to elevate the treatment and rival Abbvie/Genmab’s drug.
To Ginna Laport, Genentech’s Global Head of Lymphoma and Chronic Lymphocytic Leukaemia Development, Columvi’s biggest differentiator and distinct advantage is its fixed duration for treatment.
Laport stated that compared to the usual approach of treatment until a cessation of progression, this programme “allows patients for treatment-free interval, [and] it decreases the chance of long-term side effects,” in an interview from the American Society of Clinical Oncology Annual Meeting.
Related News
-
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News Roche breaks into the obesity drug market with the acquisition of Carmot Therapeutics
In a bid to diversify their therapeutic offerings, Roche takes over Carmot Therapeutics in $2.7 billion deal, with one obesity drug spearheading the venture into the field as they prep for a Phase II in-human trial. -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News Women in Pharma: Delivering solutions for gender diversity
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona Speaker Interview – What the US FDA’s Quality Management Maturity Means for the Pharma Industry
At CPHI Barcelona (24–26 October, 2023), we spoke to Sireesha Yadlapalli, CEO of Pharmatech Associates, who gave a presentation on the implications of the US FDA’s Quality Management Maturity (QMM) Initiative, and spoke on the panel of the ... -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Wegovy and weight-loss drugs driving demand for manufacturers that can fill syringes
Injectable weight-loss treatments are prompting contract manufacturers to invest and include fill-finish services into their service portfolios, in a bid to attract pharmaceutical giants developing drugs similar to Novo Nordisk's Wegovy.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance